Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali

Modibo Diarra 1,*; Drissa Coulibaly 1; Amadou Tapily 1; Boureima Guindo 1; Koyalu Sanogo 1; Diakalia Koné 2; Youssouf Koné 1; Karim Koné 1; Aboudramane Bathily 3; Oumar Yattara 3; Mahamadou A. Thera 1; Alassane Dicko 1; Abdoulaye A. Dijimé 1; and Issaka Sagara 1,*

Abstract: In Mali, since 2007, artemether-lumefantrine has been the first choice against uncomplicated malaria. Despite its effectiveness, a rapid selection of markers of resistance to partner drugs has been documented. This work evaluated the treatment according to the World Health Organization’s standard 28-day treatment method. The primary endpoint was the clinical and parasitological response corrected by a polymerase chain reaction. It was more than 99.9 percent, the proportion of patients with anemia significantly decrease compared to baseline (p < 0.001), and no serious events were recorded. Plasmodium falciparum remains sensitive to artemether-lumefantrine in Mali.

Keywords: malaria; Plasmodium falciparum; artemether-lumefantrine; in vivo efficacy; Mali

1. Introduction

In the past two decades, we have witnessed a revolution in the diagnosis and treatment of malaria worldwide. In sub-Saharan Africa, classical antimalarial drugs have been gradually abandoned in favor of faster and more effective molecules, mainly because of the increasing resistance of parasites [1,2]. Indeed, artemisinin-based combination therapies (ACTs), recommended by the World Health Organization (WHO) since the beginning of the millennium [3], have been adopted in many African countries for the treatment of Plasmodium falciparum malaria, which has positively contributed to reducing the global burden of malaria [3].

In Mali, malaria remains a major health problem, with more than 2 million cases and more than 1050 deaths recorded in 2017, a case-fatality rate of 0.50‰ [4]. In addition to clinical cases and asymptomatic cases, malaria also contributes significantly to the occurrence of anemia, which has a particularly high prevalence in children under 5 years of age, with 82% and 51% in pregnant women according to the results of the Demographic and Health Survey of Mali (EDSM-V, 2012–2013). In the case of clinical malaria, the only way to avoid a fatal outcome remains rapid diagnosis and appropriate treatment. In this context, the case malaria management policy in Mali has opted for artemether-lumefantrine and artesunate-amodiaquine combinations as first lines drugs for the treatment of uncomplicated malaria [2] since the discontinuation of chloroquine therapy.

In order to promote evidence-based policy decisions, the WHO stressed the need to monitor regularly the efficacy of antimalarial drugs using standardized protocols [5].
In vivo efficacy of antimalarial as well as the evaluation of the prevalence of molecular markers associated with resistance of *Plasmodium falciparum* are essential to validate the treatment and guarantee a rapid response to the infection emergence of parasite resistance. In Mali, some studies showed a rapid selection of molecular markers of *P. falciparum* resistance to artemisinin partner drugs [2,6–11].

In Southeast Asia, reports have shown the emergence and potential spread of resistance to artemisinin [12–14], resulting in a significant reduction in the rate of parasite elimination in treated patients (half-life parasite clearance) with an artemisinin derivative alone or in combination with a partner molecule [15–18].

In an open and global world with the movement of populations, it seems appropriate to strengthen the monitoring of the effectiveness of ACTs. This study is part of the monitoring of the sensitivity of *Plasmodium falciparum* to artemether-lumefantrine in two sentinel sites of Mali’s National Malaria Control Program (NMCP) during two malaria transmission seasons 2017–2018.

2. Materials and Methods

Study sites and malaria in Mali: The study was conducted according to WHO standard in vivo efficacy protocol [19] in two NMCP sentinel sites, namely: (1) the Bougouni health district (Sikasso region); (2) Bandiagara Health District, (Mopti Region). In Mali, malaria transmission is seasonal. It spans from June to December, with a peak in October–November depending on the duration of the rain. The level of endemicity is also highly variable depending on the geographical area (Bougouni is in a Sudano-Guinean zone, and Bandiagara, a Sahelo-Sudanian zone. Both districts are intense and highly seasonal malaria transmission areas with longer transmission duration at Bougouni district).

The work took place in three community health centers in Bougouni district (Bougouni East, Bougouni West and Koumantou) and a district hospital in the Bandiagara district between July 2017 and December 2018.

Patients: The study population included patients aged six months or older with uncomplicated acute malaria confirmed by microscopy. Other inclusion criteria included body weight $\geq 5$ kg, presence of fever (axillary $\geq 37.5^{\circ}$C) or a history of fever in the previous 24 h, *Plasmodium falciparum* mono-infection with asexual blood density $\geq 1000/\mu$L and $<200,000/\mu$L, and the absence of severe signs of complicated malaria as defined by WHO [20]. The main exclusion criteria included mixed malarial infections, hemoglobin level $<5$ g/dL, severe malnutrition, antimalarial treatment during the previous two weeks, ongoing prophylaxis in HIV-positive patients with cotrimoxazole or taking any other drug with antimalarial activity and any underlying serious illness. Patients meeting the inclusion criteria were enrolled if the parent/legal guardian signed a detailed written informed consent.

Treatment: Eligible patients were treated with Artemether Lumefantrine (each tablet containing 20 mg artemether and 120 mg lumefantrine). The study drug used was provided to the local health facilities by the Malian Ministry of Health. The dosage and method of administration of the drugs followed the manufacturer’s instructions and the Mali NMCP malaria treatment guideline. One dose at baseline (time 0), a second dose 8 h later, the third dose 24 h later and the last three doses 12 h apart (six doses in total) for 3 days. The number of tablets to be taken was determined according to body weight: one tablet for children from 5 to $<15$ kg, two tablets for children from 15 to $<25$ kg and three tablets for subjects of 25 to $<35$ kg and four tablets for subjects over 35 kg. Drug administrations were directly observed by the investigators. When vomiting occurred within 30 min of dosing, a new dose was re-administered. For febrile subjects (fever $> 37.5^{\circ}$C), paracetamol was used. In the event of signs of danger or severe malaria, the patient was hospitalized and given injectable artesunate, in accordance with the National Malaria Treatment Policy [3].

Follow-up: Follow-up visits took place on days 1, 2, 3, 7, 14, 21 and 28 after enrollment or at any time when the child was ill. Patients who withdrew their consent or participation were stopped prematurely for various reasons were followed through local guides until
the end of the study. Adverse events that occurred were recorded, treated, and assessed by severity and drug-study relationship. Parasite clearance was monitored by microscopy. Microscopy slides were obtained and then stained with Giemsa later prior to each dose of AL and at each follow-up visit on days 2, 3, 7, 14, 21, and 28. The slides were examined by certified microscopists and were considered negative in the absence of parasites after examination of 200 fields in a thick smear of blood according to MRTC standard operating procedures. The parasite density was estimated by counting the number of asexual parasites in 200 white blood cells, assuming a standard count of 8000/µL. The determination of the species (and thus the confirmation of the mono-infection) was carried out on the basis of an evaluation of the thin films. As part of quality control measures, a second independent microscopist from the project team read 10% of all smears from all visits.

Dried blood spots (DBS) for Polymerase Chain Reaction (PCR) analysis were collected from each patient using 3MM Whatman™ filter papers at enrolment (day 0) and at 7, 14, 21 and 28 days, on the day of treatment failure or any other unplanned visits with suspected malaria. After drying, they were stored in plastic bags containing silica gel (desiccant) and were used to distinguish the recrudescence of a new infection using the procedures recommended by WHO [19]. For participants with recurrent parasitemia after day 7, paired dried blood spots (DBS) from day 0 and the day of parasite recurrence were genotyped for Plasmodium merozoite surface protein 2 genes (msp2) and microsatellite (CA1 and TA87) to discriminate reinfection from recrudescence as described previously [21–23]. Recrudescence was defined by at least one identical allele for each of the three markers in the pretreatment and posttreatment samples. New infections were diagnosed when all alleles of at least one of the markers differed between the two samples. Cases of new infections were excluded from the per-protocol analysis. A sequential approach was used to perform the PCR.

Study outcomes: The main measured outcome of the efficacy of AL was the adequate clinical and parasitological response (ACPR) at day 28 corrected by PCR. Then, early treatment failure (ETF), late clinical failure (LCF) and late parasitological failure (LPF) as defined by the WHO [19] were also determined. Secondary outcomes included uncorrected 28-day ACPR (crude efficacy), clearance of fever and gametocytes, tolerability, and changes in baseline hemoglobin at day 7 and day 28.

Data management and statistical analysis: The data were recorded using electronic case report forms with the open data kits software (ODK). All survey questionnaires were captured using a digital tablet and sent to a database hosted in a server at the Malaria Research and Training Center at the University of Science, Techniques and Technologies of Bamako (USTTB), Mali. Tablets were secured by an individual password and kept under seal outside working hours. Efficacy was calculated in the protocol-treated population, which includes all patients meeting the eligibility criteria of the protocol, having completed the three-day treatment of the study drug, having adhered to all study procedures until a possible failure or at the final evaluation of 28th day. Efficacy rates were calculated by dividing the number of patients with clinical and parasitological cure at day 28 by the total number of patients that could be assessed. In addition, statistical analyses (proportions, descriptive statistics or percentage comparison) were performed with the R version 3.4.3 software and the statistical significance level was set at 5%.

Sample size calculations: Previous studies in Mali found artemether-lumefantrine efficacy of at least 95% in the different research sites [24,25]. The sample size calculations were based on WHO methodologies [26] using a slightly more conservative expected efficiency estimate (95%) and a precision level of about 5%. To achieve this, and with a projected loss of follow-up rate of 20% by day 28, a minimum of 117 patients should be recruited, rounded to 120 subjects on each of the study sites.

Ethical considerations: The protocol was approved by the Ethics Committee of the Faculty of Medicine and Odonto-Stomatology and Pharmacy (FMOS-FAPH) of Mali before the start of all activities (Ref N° 2017/108/CE/FMPOS) and at the amendment for the extension of the study to 2018 (Ref N° 2018/108Bis/CE/FMOS). The trial was conducted...
in accordance with the guidelines of good clinical practice. Written informed consent was obtained from all participants. Informed assent was also obtained from children aged 12 to 17 years.

3. Results

3.1. Participant Flow

Trial profile and baseline characteristics: A total of 432 febrile patients or patients with a history of fever within 24 h were screened between July 2017 and December 2018, of whom 375 (86.8%) were recruited and 330 (95.7%) completed the study, with or without recurrent parasitemia (Figure 1).

Figure 1. Study profile in both study sites during both seasons. * Parasitological failures are excluded as these were reinfections and not recrudescences.

3.2. Baseline Data

The absence of *Plasmodium falciparum* mono-infection or the presence of danger signs such as vomiting or the notion of taking other antimalarials within two weeks or during follow-up and withdrawal of consent were the main causes of exclusion. Table 1 summarizes the basic characteristics of the two sites during the two seasons of the study.

3.3. Efficacy

During the 28-day follow-up during the two malaria transmission seasons 2017 and 2018, 13 patients (9 patients, 2017 season; 7.1% and 4 patients, 2018 season; 3.2%) did not successfully complete the study due to loss of follow-up, withdrawal of consent or other protocol violations such as the accidental or deliberate taking of antimalarial drugs, incoercible vomiting after inclusion or noncompliance with the visit schedule. Reported fever was the main recorded sign at the enrollment with 79.2% of the patients. This frequency decreased rapidly during the first 48 h of follow-up, to 2% or less throughout the rest of the follow-up (Figure 2).
Table 1. Basic characteristics of subjects enrolled according to the study season in both sites.

| Parameters at Inclusion | Bougouni 2017 N = 126 | Bougouni 2018 N = 124 | Bandiagara 2017–2018 N = 125 |
|-------------------------|------------------------|-----------------------|-------------------------------|
| Age (Year) Average (range) | 10.6 (2–40)          | 11.0 (2–60)          | 11.5 (1–36)                   |
| Age groups, n (%)        |                        |                      |                               |
| ≤5 years                 | 17 (15.6)              | 23 (18.5)            | 13 (10.4)                     |
| 6–12 years               | 64 (58.7)              | 69 (55.6)            | 75 (60.0)                     |
| ≥13 years                | 28 (25.7)              | 32 (25.8)            | 37 (29.6)                     |
| Sex, n (%)               |                        |                      |                               |
| Male                     | 39 (36.1)              | 57 (46.0)            | 35 (36.5)                     |
| Female                   | 69 (63.9)              | 67 (54.0)            | 61 (63.5)                     |
| Average weight (kg) (range) | 30.1 (6.0–96.3)       | 29.5 (8.6–83.1)      | 34.1 (10–90)                  |
| Average temperature (°C) (range) | 37.6 (35.7–40)   | 38.2 (35.8–41.3)     | 38.2 (35.8–40.7)              |
| Fever (≥37.5 °C), n (%)  | 89 (70.6)              | 96 (77.4)            | 99 (79.2)                     |
| Vomiting, n (%)          | 7 (5.6)                | 21 (16.9)            | 50 (40.0)                     |
| Parasite density geometric mean (range) | 33.200 (1000–190.000) | 50.426 (1040–199.320) | 41.485 (1040–181.320)         |
| Gametocytemia, n (%)     | 0                      | 5 (4.0)              | 7 (5.6)                       |
| Average hemoglobin (g/dL), (range) | 12.2 (9.1–16)   | 11.8 (8.1–17.7)      | 12.2 (8.0–16)                 |
| Anemia (Hb < 11 g/dL), n (%) | 31 (24.6)            | 41 (33.1)            | 22 (17.6)                     |

Figure 2. Proportion of patients with axillary temperature ≥37.5 °C in both sites during the 28-day follow-up.

The treatment results by locality according to season are summarized in Table 2. The cure rate not corrected by PCR on day 28 was 85.4% (309/362; 95% CI: 81.8–98.4). All 53 cases of recurrent parasitemia were found to be new infections according to PCR, resulting in a PCR-corrected cure rate of 100.0% (309/309) for the 28-day follow-up. Thus, the cure rate corrected by PCR on day 28 was identical at both study sites.
Table 2. Treatment outcomes on day 28, according to the study season in both sites in Mali.

| Variable                              | Bougouni 2017 | Bougouni 2018 | Bandiagara 2017–2018 | Total |
|---------------------------------------|---------------|---------------|----------------------|-------|
| ACPR (uncorrected) n                  | 103           | 87            | 119                  | 309   |
| ETF b n                               | 0             | 0             | 0                    | 0     |
| LCF c n                               | 0             | 0             | 0                    | 0     |
| LPF d n                               | 14            | 33            | 6                    | 53    |
| New infections (with PCR) n           | 14            | 33            | 6                    | 53    |
| Recrudescences (with PCR) n           | 0             | 0             | 0                    | 0     |
| No treatment outcome (loss to follow-up or withdrawn) n | 9 | 4 | 0 | 13 |

**PP** e day-28 efficacy

| (PCR-uncorrected) n/N (%), IC         | 103/117       | 87/120        | 119/125              | 309/362 |
| (PCR-corrected) n/N (%)               | (88.0, 82.1–93.9) | (72.5, 64.5–80.5) | (95.0, 91.2–98.8) | (85.4, 81.8–98.4) |

ACPR: adequate clinical and parasitological response; ETF: early treatment failure; LCF: late clinical failure; LPF: late parasitological failure; PP: per-protocol.

For both locations, 50.9% of treated patients eliminated their parasitemia at the end of the first 48 h of follow-up, while 93.1% (22/439) did it at the end of the first 60 h of follow-up, and only 0.3% did not eliminate parasites at the end of the first 72 h of follow-up (Figure 3).

We also used a parasite clearance estimator from The Worldwide Antimalarial Resistance Network (WWARN) [27]. The estimated time in hours to reduce parasitemia by 99% of its initial value was 21.0 h for Bandiagara, 26.9 and 32.3 h for Bougouni in 2018 and 2017, respectively (Figure 4).

The WHO indicated Kaplan–Meier survival analysis [26] assessing the uncorrected treatment efficacy showed a significant difference ($p < 0.0001$) between the study sites (Figure 5).
Figure 3. Proportion of patients with parasitemia in both sites during the first 72 h of follow-up.

We also used a parasite clearance estimator from The Worldwide Antimalarial Resistance Network (WWARN) [27]. The estimated time in hours to reduce parasitemia by 99% of its initial value was 21.0 h for Bandiagara, 26.9 and 32.3 h for Bougouni in 2018 and 2017, respectively (Figure 4).

Figure 4. Median time required to eliminate 90%, 95% and 99% of parasitemia (hours) per site.

The WHO indicated Kaplan–Meier survival analysis [26] assessing the uncorrected treatment efficacy showed a significant difference ($p < 0.0001$) between the study sites (Figure 5).

There was zero percent parasite recrudescence at all sites after molecular correction for reinfection.

The list of all the participants (n = 53) who had reinfection is provided in Appendix A.

Figure 5. Kaplan–Meier survival curve showing artemether-lumefantrine PCR uncorrected efficacy over 28 days of follow-up period per study site and year.
3.4. Tolerability and Safety

Fourteen patients reported vomiting (14/375; 3.7%) during the three days of treatment in both locations (Table 3). Twenty-one episodes of abdominal pain (21/375; 5.6%), twelve episodes of headache (12/375; 3.2%) and eleven episodes of diarrhea (11/375; 2.9%) occurred in both locations; all of these events were transient and mild in nature (Table 3). These events could be related to malaria or the study drug.

Table 3. Cumulative adverse events related to tolerability during the three days of treatment for both study sites in Mali.

| Artemether-Lumefantrine | Bougouni, 2017 N = 126 | Bougouni, 2018 N = 124 | Bandiagara, 2017–2018 N = 125 | Total N = 375 |
|-------------------------|------------------------|-----------------------|-------------------------------|---------------|
| Vomiting post-dosing 1, 2 or 3 n (%) | 1 (0.8) | 4 (3.2) | 9 (7.2) | 14 (3.7) |
| Diarrhea n (%) | 3 (2.4) | 1 (0.8) | 7 (5.6) | 11 (2.9) |
| Abdominal pain n (%) | 3 (2.4) | 8 (6.5) | 10 (8.0) | 21 (5.6) |
| Headaches n (%) | 0 (0) | 8 (6.5) | 4 (3.2) | 12 (3.2) |

The proportion of patients with hemoglobin below 11 g/dL at inclusion (94/375; 25.1%) was significantly improved on day 28 (60/330; 18.2%). This improvement was observed in all localities and in both seasons for the Bougouni site (Table 4). However, no improvement of hemoglobin was observed on day 7 of the follow-up compared to day 0. No serious adverse events (SEs) were documented in this study.

Table 4. Proportion of patients with hemoglobin <11 g/dL between day 0 and day 28 in both sites.

| Sites | Anemia | McNemar’s Test p Value |
|-------|--------|------------------------|
| Day 0 | Day 28 |                        |
| Bougouni, 2017 % (n/N) | 24.6 (31/126) | 16.0 (17/106) | <0.001 |
| Bougouni, 2018 % (n/N) | 33.1 (41/124) | 28.8 (32/111) | <0.001 |
| Bandiagara, 2017–2018 % (n/N) | 17.6 (22/125) | 9.7 (11/113) | <0.001 |
| Total % (n/N) | 25.1 (94/375) | 18.2 (60/330) | <0.001 |

4. Discussion

This study describes the 28-day in vivo efficacy of AL under field conditions at two NMCP sentinel sites in Mali. These two sites, one Guinean Sudanese area, the other Sahelian area, provide a good geographical representation of the variability of malaria endemicity and transmission patterns in the country. The standard protocol for evaluating the in vivo efficacy of WHO ACTs was used at both sites [26], including molecular techniques for differentiation of new infections from recrudescences [19]. In this work, when recruiting patients, we have taken into account the realities on the ground to make it easier to achieve height by setting the inclusion parasitemia at 1000 trophozoite/µL of blood and extending recruitment to all patients who consulted the study centers. Despite these measures, the Bandiagara site took two transmission seasons to reach sample size. The other peculiarity of this work was the use of existing artemether-lumefantrine stocks in the health facilities where the study took place therefore the local storage conditions of the drugs that being used to treat malaria daily by the local health centers. Thus, artemether-lumefantrine provided by the local health facilities and used appeared to be efficacious, safe and well-tolerated as there were no serious adverse events, and the adverse events reported were minor and mostly unrelated to the study product. All episodes of vomiting occurred in patients with suspected vomiting after the first 30 min of treatment and therefore did not require dose re-administration except in two cases that were more likely to be drug rejections. No cases of repeated vomiting or changes in treatment have been reported. In addition, the occurrence of other adverse events during follow-up was rare. It also
appeared that the proportion of patients with hemoglobin levels <11 g/dL was significantly reduced between enrollment and the end of the study at day 28. This trend was comparable to what other authors have described using artemether-lumefantrine [14]. On the other hand, seven days after the start of treatment, no effect was observed on the proportion of patients with hemoglobin ≥ 11 g/dL; rather, there was a significant trend in hemoglobin decrease.

From the point of view of efficacy, the cure rate corrected by PCR (>99.9%) remains high and adequate according to WHO recommendations. These results confirm those of previous studies in Mozambique and Myanmar, all of which have documented the efficacy and safety of the combination of artemether-lumefantrine [28,29].

The study was not designed to compare sites, so caution should be exercised in interpreting results such as late parasitological failure (LPF) levels, Es identified and the effect of treatment on hemoglobin recovery. Parasitic clearance was obtained at the sites within the first 72 h after treatment, apyrexia without analgesia was obtained 48 h after treatment as documented in 2016 in Mali [18], a reassuring sign regarding the issue of resistance raised by some authors [30,31].

Difficulties encountered were on the respect of the AL dose taking schedules, which often occurred late at night. In order to minimize the inconveniences linked to this situation, the investigators took the participants’ telephone number with their agreement and called them an hour or thirty minutes in advance or went directly to the participants’ homes with the help of the local guide if they encountered a problem in coming to the health center to take the doses. The same strategy was used for parasitological follow-up (every 12 h) until two consecutive negative thick blood smears were obtained. On the other hand, the 28-day follow-up time was also difficult because it was considered long and contributed to a relatively high number of people lost to follow-up.

The molecular genotyping with msp1, msp2 and The Glutamate-Rich Protein (GLURP) is commonly used to distinguish recrudescence from reinfection in the monitoring of antimalarial drug efficacy [32–36]. In this study, we have performed the genotyping on the 53 episodes of recurrent parasitemia to support their classification as new infections using msp2, PfCA1 and PfTA99 as usually performed here as described previously [21–23], which allows for the efficacy data comparison locally. The enrollment of participants with 1000 parasites/µL or above instead of 2000 parasites/µL or above may be a limitation of the study. However, we believe that this does not affect the validity of our results as malaria control strategies are rapidly changing the malaria epidemiology in malaria-endemic areas [3].

In addition, efforts are underway to perform the parasite molecular resistance of *Plasmodium falciparum* to antimalarial using the 53 episodes of recurrent parasitemia samples and the results will be published.

Continuous monitoring of the in vivo efficacy of artemether-lumefantrine across the country is necessary to detect early signs of decreased efficacy of artemether-lumefantrine.

5. Conclusions

This study showed high efficacy of AL against *Plasmodium falciparum* malaria after more than a decade of use of this drug and was safe and well-tolerated. The findings of this study advocate for the continuous use of AL as first-line therapy for uncomplicated malaria in Mali. However, a genotyping of the parasite molecular resistance to antimalarial is needed to support these findings, and the monitoring of AL efficacy should continue as recommended by WHO.

**Author Contributions:** M.D. and D.C. developed the study concept, wrote the protocol, and wrote the paper. I.S. and A.D. validated the final protocol and critically edited the paper. M.D.; D.C.; A.T.; B.G.; D.K.; Y.K.; K.K.; A.B.; O.Y., and K.S. were involved in protocol development, data collection, and clinical and laboratory investigations. M.D. and I.S. performed the statistical data analysis and edited. M.A.T.; A.D and A.A.D. critically reviewed the manuscript, validated consent and ethical procedures. All authors have read and agreed to the published version of the manuscript.
Funding: This work was supported by Mali’s National Malaria Control Program through the Global Fund to Fight Malaria’s Principal Recipient, Population International Service, Mali (PSI-Mali).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Ethics Committee of Faculty of Medicine and Odonto-Stomatology and the Faculty of Pharmacy, University of Sciences Techniques and Technology of Bamako, Mali (protocol code: 2017/108/CE/FMPOS, August 17th 2017 and 2018/108 Bis/CE/FMPOS, September 14th, 2018).

Informed Consent Statement: Informed consent was obtained from all subjects participating in the study and was accompanied by assent for all participating subjects aged 12 to 17 years.

Data Availability Statement: Our study has one limitation in relation to the data availability policy. Indeed, this aspect was not taken into account during the process of obtaining informed consent from the study subjects nor during the process of obtaining ethics committee approval. In addition to this, the data on molecular markers of artemether-lumefantrine resistance will be specifically analyzed and the resulting results will be the subject of another manuscript.

Acknowledgments: This work was made possible thanks to the Global Fund grant for the fight against malaria through the International Population Service (PSI) Mali, the Mali National Malaria Control Program. We also thank the staff of the Bougouni and Bandiagara health districts and partner health centers, the populations of the study sites, the authorities and the teams of the Malaria Research and Training Center, University of Technology and Technical Sciences of Bamako (USTTB), Mali. We also thank to A.T. for protocol development, data collection, and clinical and laboratory investigations.

Conflicts of Interest: The authors declare that they have no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Appendix A

Table A1. Results of molecular analysis by study site and season.

| ID Patient | Visit Days | Study Sites | Pfmsp2 | PfCA1 | PfTA99 | Outcome |
|------------|------------|-------------|--------|-------|--------|---------|
| BOS006     | D0         | Bougouni A  | A      |       |        |         |
| BOS006     | D21        | Bougouni B  |        |       |        |         |
| BOS009     | D0         | Bougouni B  | B      |       |        |         |
| BOS009     | D28        | Bougouni AC |        |       |        |         |
| BOS017     | D0         | Bougouni A  | A      |       |        |         |
| BOS017     | D28        | Bougouni B  |        |       |        |         |
| BOS051     | D0         | Bougouni A  | A      | BC    |        |         |
| BOS051     | D28        | Bougouni BC |        |       |        |         |
| BAD052     | D0         | Bandiagara B |       |       |        |         |
| BAD052     | UV         | Bandiagara A |       |       |        |         |
| BAD049     | D0         | Bandiagara A |       |       |        |         |
| BAD049     | D21        | Bandiagara B |       |       |        |         |
| BOS059     | D0         | Bougouni A  | A      |       |        |         |
| BOS059     | D28        | Bougouni B  |        |       |        |         |
| BOS075     | D0         | Bougouni A  | A      |       |        |         |
| BOS075     | D21        | Bougouni B  |        |       |        |         |
| BOS085     | D0         | Bougouni A  | A      | C     |        |         |
| BOS085     | D28        | Bougouni AB  |       |       |        |         |
| BOS109     | D0         | Bougouni A  | A      |       |        |         |
| BOS109     | D28        | Bougouni B  |        |       |        |         |
Table A1. Cont.

| ID Patient | Visit Days | Study Sites | Pfmsp2 | PfCA1 | PfTA99 | Outcome |
|------------|------------|-------------|--------|-------|--------|---------|
| Season 2017, Total: 14 |
| BOS114     | D0         | Bougouni    | A      |       |        | 1       |
| BOS114     | D28        | Bougouni    | B      |       |        |         |
| BOS115     | D0         | Bougouni    | AB     |       |        | 1       |
| BOS115     | D21        | Bougouni    | CD     |       |        |         |
| BOS129     | D0         | Bougouni    | A      |       |        | 1       |
| BOS129     | D21        | Bougouni    | B      |       |        |         |
| BOS163     | D0         | Bougouni    | AB     | AB    |        | 1       |
| BOS163     | D21        | Bougouni    | A      | C     |        |         |
| Season 2018, Total: 39 |
| BOK001     | D0         | Bougouni    | A      | B     |        | 1       |
| BOK001     | D28        | Bougouni    | 9      | A     |        |         |
| BOK002     | D0         | Bougouni    | AC     | A     |        | 1       |
| BOK002     | D21        | Bougouni    | AB     | B     |        |         |
| BOK003     | D0         | Bougouni    | A      | A     |        | 1       |
| BOK003     | D21        | Bougouni    | BC     | B     |        |         |
| BOK009     | D0         | Bougouni    | AB     | A     |        | 1       |
| BOK009     | D28        | Bougouni    | B      | B     |        |         |
| BOK013     | D0         | Bougouni    | AB     | A     |        | 1       |
| BOK013     | D21        | Bougouni    | 9      | B     |        |         |
| BOK016     | D0         | Bougouni    | A      | A     |        | 1       |
| BOK016     | D28        | Bougouni    | 9      | B     |        |         |
| BOK019     | D0         | Bougouni    | A      |       |        | 1       |
| BOK019     | D28        | Bougouni    | B      |       |        |         |
| BOK020     | D0         | Bougouni    | AB     | B     |        | 1       |
| BOK020     | D28        | Bougouni    | B      | A     |        |         |
| BOK024     | D0         | Bougouni    | A      | A     |        | 1       |
| BOK024     | D28        | Bougouni    | 9      | B     |        |         |
| BOK025     | D0         | Bougouni    | A      | B     |        | 1       |
| BOK025     | D28        | Bougouni    | A      | A     |        |         |
| BOK026     | D0         | Bougouni    | A      | B     |        | 1       |
| BOK026     | D28        | Bougouni    | B      | A     |        |         |
| BOK028     | D0         | Bougouni    | 9      | A     |        | 1       |
| BOK028     | D28        | Bougouni    | A      | B     |        |         |
| BOK030     | D0         | Bougouni    | B      |       |        | 1       |
| BOK030     | D21        | Bougouni    | A      |       |        |         |
| BOK031     | D0         | Bougouni    | BD     | AC    |        | 1       |
| BOK031     | D21        | Bougouni    | AC     | B     |        |         |
| BOK038     | D0         | Bougouni    | B      | A     | A      | 1       |
| BOK038     | D21        | Bougouni    | ABC    | 9     | B      |         |
| BOK044     | D0         | Bougouni    | B      |       |        | 1       |
| BOK044     | D28        | Bougouni    | A      |       |        |         |
| BOK048     | D0         | Bougouni    | AB     | A     | A      | 1       |
| BOK048     | D28        | Bougouni    | A      | A     | B      |         |
| BOK050     | D0         | Bougouni    | AB     | A     |        | 1       |
| BOK050     | D21        | Bougouni    | C      | B     |        |         |
| BOK053     | D0         | Bougouni    | A      | A     | AC     | 1       |
| BOK053     | D14        | Bougouni    | 9      | A     | B      |         |
Table A1. Cont.

| ID  | Patient | Visit Days | Study Sites | Pfmsp2 | PfCA1 | PfTA99 | Outcome |
|-----|---------|------------|-------------|--------|-------|--------|---------|
| BOK058 | D0   | Bougouni | A           |        |       |        | 1       |
| BOK058 | D28  | Bougouni | B           |        |       |        |         |
| BOK059 | D0   | Bougouni | A           | A      | A     |        | 1       |
| BOK059 | D28  | Bougouni | A           | B      | B     |        |         |
| BOK060 | D0   | Bougouni | ACD         | A      |       |        | 1       |
| BOK060 | D28  | Bougouni | AB          | B      |        |        |         |
| BOK062 | D0   | Bougouni | ABD         |        |       |        | 1       |
| BOK062 | D28  | Bougouni | C           |        |       |        |         |
| BOO003 | D0   | Bougouni | AD          | A      |       |        | 1       |
| BOO003 | D21  | Bougouni | AB          | B      |        |        |         |
| BOO029 | D0   | Bougouni | AC          | B      |       |        | 1       |
| BOO029 | D21  | Bougouni | B           | A      |        |        |         |
| BOO018 | D0   | Bougouni | ABD         | B      |        |        | 1       |
| BOO018 | D28  | Bougouni | 9           | B      |        |        |         |
| BOO019 | D0   | Bougouni | C           |        |       |        | 1       |
| BOO019 | D28  | Bougouni | AB          |        |       |        |         |
| BOO025 | D0   | Bougouni | AB          | B      |       |        | 1       |
| BOO025 | D28  | Bougouni | A           | A      |        |        |         |
| BOO052 | D0   | Bougouni | AB          | A      | AC    |        | 1       |
| BOO052 | D28  | Bougouni | 9           | A      | B     |        |         |
| BOO045 | D0   | Bougouni | B           |        |       |        | 1       |
| BOO045 | D21  | Bougouni | A           |        |       |        |         |
| BOO057 | D0   | Bougouni | A           | B      |       |        | 1       |
| BOO057 | D28  | Bougouni | AB          | A      |        |        |         |
| BOO072 | D0   | Bougouni | AB          | A      | B     |        | 1       |
| BOO072 | D28  | Bougouni | A           | 9      | A     |        |         |
| BOO073 | D0   | Bougouni | AD          |        |       |        | 1       |
| BOO073 | D21  | Bougouni | B           |        |       |        |         |
| BAD077 | D0   | Bandiagara | AB         | A      |       |        | 1       |
| BAD077 | D21  | Bandiagara | B         | B      |        |        |         |
| BAD081 | D0   | Bandiagara | B         | A      | A     |        | 1       |
| BAD081 | D26  | Bandiagara | AB        | 9      | B     |        |         |
| BAD088 | D0   | Bandiagara | A         | A      |       |        | 1       |
| BAD088 | D28  | Bandiagara | AB        | B      |        |        |         |
| BAD097 | D0   | Bandiagara | AB         |        |       |        | 1       |
| BAD097 | D21  | Bandiagara | C         |        |       |        |         |
| BAD101 | D0   | Bandiagara | A         |        |       |        | 1       |
| BAD101 | D21  | Bandiagara | CD        |        |       |        |         |
| BAD120 | D0   | Bandiagara | D         |        |       |        | 1       |
| BAD120 | D28  | Bandiagara | A         |        |       |        |         |

Table legend: letters A, B, C and D: band length. Number 9: no band.

References

1. Trape, J.F. The public health impact of chloroquine resistance in Africa. *Am. J. Trop. Med. Hyg.* 2001, 64, 12–17. [CrossRef] [PubMed]
2. Tekete, M.; Djimde, A.A.; Beavogui, A.H.; Maiga, H.; Sagara, I.; Fofana, B.; Ouologuem, D.; Dama, S.; Kone, A.; Dembele, D.; et al. Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: Revisiting molecular markers in an area of emerging AQ and SP resistance in Mali. *Malar. J.* 2009, 8, 34. [CrossRef] [PubMed]
3. Reyburn, H. New WHO guidelines for the treatment of malaria. *Br. Med. J. Publ. Group* 2010. [CrossRef] [PubMed]
4. Boli, M. PNLP: Objectif, zéro paludisme au Mali à l’horizon 2030. JSTM 2019. Available online: https://www.jstm.org/prnlp-objectif-zero-paludisme-au-mali-a-lhorizon-2030/ (accessed on 11 November 2020).

5. WHO. World Malaria Report 2018; World Health Organization: Geneva, Switzerland, 2018. Available online: http://www.who.int/malaria/publications/world-malaria-report-2018/en/ (accessed on 19 November 2020).

6. WHO. Assessment of Therapeutic Efficacy of Antimalarial Drugs: For Uncomplicated Falciparum Malaria in Areas with Intense Transmission; World Health Organization: Geneva, Switzerland, 1996. Available online: https://apps.who.int/iris/handle/10665/63295 (accessed on 19 November 2020).

7. Profile_mli_en.pdf. Available online: https://www.who.int/malaria/publications/country-profiles/profile_mli_en.pdf (accessed on 19 November 2020).

8. Kaddour, H.; Djimdé, A.; Dama, S.; Kodio, A.; Tekete, M.; Hubert, V.; Koné, A.; Maiga, H.; Yattara, O.; Fofana, B.; et al. Baseline in vitro efficacy of ACT component drugs on Plasmodium falciparum clinical isolates from Mali. Int. J. Parasitol. 2008, 38, 791–798. [CrossRef]

9. Ouattara, A.; Kane, A.; Adams, M.; Fofana, B.; Maiga, A.W.; Hampton, S.; Coulibaly, D.; Thera, M.A.; Diallo, N.; Dara, A.; et al. Polymorphisms in the K13-Propeller Gene in Artemisinin-Susceptible Plasmodium falciparum Parasites from Bougoula-Hameau and Bandiagara, Mali. Am. J. Trop. Med. Hyg. 2015, 92, 1202–1206. [CrossRef]

10. Dicko, A.; Sagara, I.; Djimdé, A.A.; Touné, S.O.; Traore, M.; Dama, S.; Diallo, A.I.; Barry, A.; Dicko, M.; Coulibaly, O.M.; et al. Molecular markers of resistance to sulphadoxine-pyrimethamine one year after administration of intermittent preventive treatment of malaria in infants in Mali. Malar. J. 2010, 9, 9. [CrossRef]

11. Djimdé, A.A.; Fofana, B.; Sagara, I.; Sidibe, B.; Toure, S.; Dembele, D.; Dama, S.; Ouologuem, D.; Dicko, A.; Dumombo, O.K. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am. J. Trop. Med. Hyg. 2008, 78, 455–461. [CrossRef]

12. Dondorp, A.M.; Nosten, F.; Yi, P.; Das, D.; Phyoo, A.P.; Tarning, J.; Lwin, K.M.; Ariey, F.; Hanpithakpong, W.; Lee, S.J.; et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 2009, 361, 455–467. [CrossRef]

13. Noedl, H.; Se, Y.; Schaecher, K.; Smith, B.L.; Socheat, D.; Fukuda, M.M.; Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 2008, 359, 2619–2620. [CrossRef]

14. WHO. Global Plan for Artemisinin Resistance Containment—GPARC (Archived); World Health Organization: Geneva, Switzerland, 2011. Available online: http://www.who.int/malaria/publications/atoz/9789241500838/en/ (accessed on 19 November 2020).

15. Flegg, J.A.; Guerin, P.J.; White, N.J. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. Trans. R. Soc. Trop. Med. Hyg. 2011, 105, 16–22. [CrossRef]

16. Duru, V.; Witkowski, B.; Ménard, D. Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperquine: A Major Challenge for Malaria Elimination in Africa. Am. J. Trop. Med. Hyg. 2016, 95, 1228–1238. [CrossRef] [PubMed]

17. Woodrow, C.J.; White, N.J. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol. Rev. 2017, 41, 34–48. [CrossRef] [PubMed]

18. Wittmer, K.; Dahalan, F.A.; Delves, M.J.; Yahiya, S.; Watson, O.J.; Strachil, U.; Chiwcharoen, D.; Sornboon, B.; Pukrittayakamee, S.; Pearson, R.D.; et al. Transmission of artemisinin-resistant malaria parasites to mosquitoes under antimalarial drug pressure. Antimicrob. Agents Chemother. 2020, 66, e00898-20. [CrossRef] [PubMed]

19. WHO. Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations; World Health Organization: Geneva, Switzerland, 2008. Available online: http://www.who.int/malaria/publications/atoz/9789241596305/en/ (accessed on 19 November 2020).

20. World Health Organization, Communicable Diseases Cluster. Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 2000, 94 (Suppl. 1), 51–590. [CrossRef]

21. Sagara, I.; Beavogut, A.H.; Zongo, I.; Soulama, I.; Borghini-Führer, I.; Fofana, B.; Camara, D.; Somé, A.F.; Coulibaly, A.S.; Traore, O.B.; et al. Safety and efficacy of artemether-lumefantrine and artesunate-amodiaquine in African patients with malaria: A substudy of the WANCEM randomised trial. Lancet Infect. Dis. 2016, 16, 189–198. [CrossRef]

22. Mugittu, K.; Adjuik, M.; Snounou, G.; Ntoumi, F.; Taylor, W.; Mshinda, H.; Olliaro, P.; Beck, H.-P. Molecular genotyping to distinguish between recrudescents and new infections in treatment trials of Plasmodium falciparum malaria conducted in Sub-Saharan Africa: Adjustment of parasitological outcomes and assessment of genotyping effectiveness. Trop. Med. Int. Health 2006, 11, 1350–1359. [CrossRef] [PubMed]

23. Ranford-Cartwright, L.C.; Taylor, J.; Umasanthar, T.; Taylor, L.H.; Babiker, H.A.; Lell, B.; Schmidt-Ott, J.R.; Lehman, L.G.; Walliker, D.; Kremsner, P.G. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans. R. Soc. Trop. Med. Hyg. 1997, 91, 719–724. [CrossRef]

24. Dama, S.; Niangaly, H.; Djimde, M.; Sagara, I.; Guindo, C.O.; Zeguime, A.; Dara, A.; Djimde, A.A.; Dumombo, O.K. A randomized trial of dihydroartemisinin–piperazine versus artemether–lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Malar. J. 2018, 17, 1–8. [CrossRef]

25. Niaré, K.; Dara, A.; Sagara, I.; Sissoko, M.S.; Guindo, C.O.; Cissé, N.H.; Coulibaly, C.K.; Ringwald, P.; Benoit-Vical, F.; Berry, A.; et al. In Vivo Efficacy and Parasite Clearance of Artesunate + Sulphadoxine-Pyrimethamine Versus Artemether-Lumefantrine in Mali. Am. J. Trop. Med. Hyg. 2016, 94, 634–639. [CrossRef]

26. WHO. Methods for Surveillance of Antimalarial Drug Efficacy; World Health Organization: Geneva, Switzerland, 2009. Available online: http://www.who.int/malaria/publications/atoz/9789241597531/en/ (accessed on 19 November 2020).
27. Parasite Clearance Estimator (PCE). Worldwide Antimalarial Resistance Network. 2015. Available online: https://www.wwarn.org/parasite-clearance-estimator-pce (accessed on 11 December 2020).

28. Nhama, A.; Bassat, Q.; Enosse, S.; Nhacolo, A.; Mutemba, R.; Carvalho, E.; Naueia, E.; Sevène, E.; Guinovart, C.; Warsame, M.; et al. In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: A multisite, open-label, two-cohort, clinical trial in Mozambique. Malar. J. 2014, 13, 309. [CrossRef]

29. Myint, M.K.; Rasmussen, C.; Thi, A.; Bustos, D.; Ringwald, P.; Lin, K. Therapeutic efficacy and artemisinin resistance in northern Myanmar: Evidence from in vivo and molecular marker studies. Malar. J. 2017, 16, 143. [CrossRef] [PubMed]

30. Das, D.; Price, R.N.; Bethell, D.; Guerin, P.J.; Stepniewska, K. Early parasitological response following artemisinin-containing regimens: A critical review of the literature. Malar. J. 2013, 12, 125. [CrossRef] [PubMed]

31. Stepniewska, K.; Ashley, E.; Lee, S.J.; Anstey, N.; Barnes, K.I.; Binh, T.Q.; D’Alessandro, U.; Day, N.P.J.; de Vries, P.J.; Dorsey, G.; et al. In vivo parasitological measures of artemisinin susceptibility. J. Infect. Dis. 2010, 201, 570–579. [CrossRef] [PubMed]

32. Rouse, P.; Mkulama, M.A.; Thuma, P.E.; Mharakurwa, S. Distinction of Plasmodium falciparum recrudescence and re-infection by MSP2 genotyping: A caution about unstandardized classification criteria. Malar. J. 2008, 7, 185. [CrossRef] [PubMed]

33. Felger, I.; Tavul, L.; Kabintik, S.; Marshall, V.; Genton, B.; Alpers, M.; Beck, H.P. Plasmodium falciparum: Extensive polymorphism in merozoite surface antigen 2 alleles in an area with endemic malaria in Papua New Guinea. Exp. Parasitol. 1994, 79, 106–116. [CrossRef]

34. Beshir, K.B.; Sutherland, C.J.; Sawa, P.; Drakeley, C.J.; Okell, L.; Mweresa, C.K.; Omar, S.A.; Shekalaghe, S.A.; Kaur, H.; Ndaro, A.; et al. Residual Plasmodium falciparum Parasitemia in Kenyan Children After Artemisinin-Combination Therapy Is Associated With Increased Transmission to Mosquitoes and Parasite Recurrence. J. Infect. Dis. 2013, 208, 2017–2024. [CrossRef]

35. Sawa, P.; Shekalaghe, S.A.; Drakeley, C.J.; Sutherland, C.J.; Mweresa, C.K.; Baidjoe, A.Y.; Manjurano, A.; Kavishe, R.A.; Beshir, K.B.; Yussuf, R.U.; et al. Malaria Transmission After Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine: A Randomized Trial. J. Infect. Dis. 2013, 207, 1637–1645. [CrossRef]

36. Beshir, K.B.; Diallo, N.; Sutherland, C.J. Identifying Recrudescent Plasmodium falciparum in Treated Malaria Patients by Real-time PCR and High Resolution Melt Analysis of Genetic Diversity. Sci. Rep. 2018, 8, 1–10. [CrossRef]